Preclinical
NUCLEAR
Medicine
In various preclinical studies in this area, the antiproliferative and cytotoxic effects, biodistribution, and toxicity of new metal-based drugs and radiopharmaceuticals are evaluated, as well as their potential mechanisms of action in inflammation and other relevant cancer signaling pathways – driving the other CancerThera research efforts.
Sérgio Brunetto
Coordenador
Preclinical Research
in Nuclear Medicine
In addition to conventional evaluation, Preclinical Research in Nuclear Medicine carries out radiolabeling and imaging exams using microPET, small animal SPECT/CT, medium-sized animal SPECT, and investigates antiproliferative activity and cell death assays in tumor cell lines. CancerThera’s Preclinical Nuclear Medicine actions take place in the Preclinical Imaging Laboratory at the School of Medical Sciences of Unicamp.